Loading...

Latest News

Still 1 PhD position open!

June 7, 2021|News|


PhD student 8 – High-throughput screening of endosomes in different metabolic/genetic backgrounds

Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, ES
Albert Pol, apols[at]ub.edu

The PhD student will implement improved methods to purify endosomes from rat [read more…]

About Metabolic Syndrom

Metabolic syndrome (MetS) is a collection of pathological conditions that include abdominal obesity, increased blood pressure, insulin resistance and increased blood glucose and lipids. MetS is a risk factor for type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). Combined, these cardio-metabolic diseases form a heavy burden on our society and health care system. Clearly, increasing our knowledge on the molecular mechanisms contributing to the maintenance of metabolic homeostasis will provide tools to improve prognosis, diagnosis and ultimately treatment of patients with cardio-metabolic diseases.

READ MORE …

About Metabolic Syndrom

Metabolic syndrome (MetS) is a collection of pathological conditions that include abdominal obesity, increased blood pressure, insulin resistance and increased blood glucose and lipids. MetS is a risk factor for type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). Combined, these cardio-metabolic diseases form a heavy burden on our society and health care system. Clearly, increasing our knowledge on the molecular mechanisms contributing to the maintenance of metabolic homeostasis will provide tools to improve prognosis, diagnosis and ultimately treatment of patients with cardio-metabolic diseases.

READ MORE …

Mission & Ambition

It is the ambition of EndoConnect to bring top scientists and industrial partners from different European countries (the Netherlands, Germany, UK, Finland, Spain, Switzerland) together to train PhD students in interdisciplinary research, with the focus on translating key findings from cellular and animal models to patients with cardio-metabolic diseases.
EndoConnect will provide an international training program for PhD students to acquire knowledge and state-of-the-art scientific, technical, and transferable skills to connect molecular and cell biology research with physiology and biomedical research towards translation. This training will significantly increase the career perspectives of PhDs and allow them to become the future leaders in this emerging interdisciplinary field, both in a scientific and societal manner.

Work Packages

About our vacancies for PhD positions

PhD positions in the Molecular Regulation and the role of Endo-Lysosomal Processes in Cardio-Metabolic diseases for the Marie-Curie Innovative Training Network “EndoConnect”

As a PhD student in EndoConnect you will be part of an international team of young researchers. You will have your individual research project at your host organisation, focusing on your discipline of interest. To broaden your specialized training, you will undertake internships at complementary EndoConnect partner organization. In addition, you will follow advanced interdisciplinary courses by leaders in the field of molecular and cell biology, metabolism, physiology and biomedical research. Thus, you will be trained to become one of the future leaders in this emerging interdisciplinary field. 

Check the PHD position that is still open

Our Team

Principal investigators & management

Project Coordinator; University Medical Center Groningen, NL

Bart van de Sluis

Project Manager

Floor Morriën

Project manager

Karen van Eunen

University of Bristol, UK

Pete Cullen

University Medical Centre Utrecht, NL

Judith Klumperman

Helmholtz Institute, Munich, DE

Anja Zeigerer

University Medical Center Hamburg-Eppendorf, DE

Jörg Heeren

University Medical Center Groningen, NL

Jan Albert Kuivenhoven

Institute D' Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES

Albert Pol

University Medical Center Hamburg-Eppendorf, DE

Pablo Sáez

AstraZeneca, UK

Helen Boyd

AstraZeneca, UK

Kevin Moreau

University of Helsinki, FIN

Elina Ikonen

Academic Medical Centre Amsterdam, NL

Noam Zelcer

Nebion, CH

Philip Zimmermann

Utrecht University, NL

Alain de Bruin

InteRNA, Utrecht, NL

Roel Schaapveld

InteRNA, Utrecht, NL

Sanaz Yahyanejad

Institute D' Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES

Marta Bosch

Project Coordinator; University Medical Center Groningen, NL

Bart van de Sluis

Dr. Bart van de Sluis graduated in Biology from the Utrecht University, the Netherlands. In 1998, he was appointed as a PhD student at the Department of Human Genetics at the Utrecht University, the Netherlands. He received his PhD degree (cum laude, highest distinction in the Netherlands) in 2002. As a post-doctoral fellow, he continued his scientific career at the Genetics and Molecular Biology Branch at the National Human Genome Research Institute (NIH, Bethesda, USA). Mid-2004, he returned back to Utrecht as a post-doc and in March 2008, he moved to Groningen to set up his own research group to further understand the molecular regulation of lipid metabolism. He is using cellular and mouse models to study these different processes in great detail. In addition, he runs a mouse transgenic mouse facility at the RUG/UMCG to generate new mouse models using different approaches, such as the CRISPR/Cas9 methodology. 

Project Manager

Floor Morriën

Floor works as a project manager at UMCG Research BV. She is involved in the post-award project management of several EU projects including MSCA Innovative Training Networks.

Project manager

Karen van Eunen

Karen works as a project manager at UMCG Research BV. She is involved in the post-award project management of several EU projects including MSCA Innovative Training Networks.

University of Bristol, UK

Pete Cullen

Prof. Peter Cullen is Professor of Biochemistry, Wellcome Trust Investigator and Medical Research Council Programme Grant Holder with the School of Biochemistry at the University of Bristol. With over 20 years of running an independent laboratory he has supervised 13 PhD students to completion. The vast majority are continuing to develop their careers as group leaders, post-docs in academic and industry, or through positions within funding agencies and medical publishing/writing.

University Medical Centre Utrecht, NL

Judith Klumperman

Judith Klumperman is cell biologist and expert in electron microscopy (EM). Her lab is internationally renowned for the use of immuno-EM and correlative light electron microscopy (CLEM). Her research is aimed to understand how genetic mutations lead to cellular disorganization and disease with focus on the endo-lysosomal pathway. Since 2018, Judith chairs the Netherlands Electron Microscopy Infrastructure’ (NEMI) for national coordinated investments in EM development, infrastructure and education.

Helmholtz Institute, Munich, DE

Anja Zeigerer

The research group leader Anja Zeigerer is functioning as PI in this project. Dr. Zeigerer conducted her PhD at Weill Cornell Medical School, NYC and obtained her degree at the University of Heidelberg in 2004. She moved on to do a first postdoc at Rockefeller University, NYC afterwards and a second one to the Max-Planck-Institute for Cell Biology and Genetics, Dresden. Now she is leading her independent research group since 2015 at the IDC in Munich.

University Medical Center Hamburg-Eppendorf, DE

Jörg Heeren

Prof. Dr. Joerg Heeren (born 1970) is Heisenberg Professor for Immunometabolism, deputy director of the Department of Biochemistry and Molecular Cell Biology at UKE. He has great experience as principal investigator in national and international collaborative research initiatives. The consortium will benefit from his expertise in metabolic studies including nanoparticle-based imaging technologies, technologies to analyse systemic and organ-specific energy metabolism, and high-throughput platform technologies to monitor organ-specific metabolomics networks in adipose tissue.

University Medical Center Groningen, NL

Jan Albert Kuivenhoven

Started out as a molecular and cellular biologist (MSc 1991 cum laude; Wageningen University Research Center, the Netherlands). He finished his PhD at the Academic Medical Center, University of Amsterdam (1996; Department of Experimental Vascular Medicine) on the genetics of high-density lipoprotein and triglyceride metabolism. Following a post-doc at the Department of Biology, Massachusetts Institute of Biology, Boston (1997-1999), where he worked on angiogenesis, he returned to Amsterdam and continued working on the genetics of human dyslipidemias. In September 2011, he moved to the University Medical Center Groningen (Department of Pediatrics) where he is heading a basic research group with strong translational focus on identification and molecular characterization of new genes with roles in lipid and lipoprotein metabolism. As of 2017, he has been appointed full Professor at the University Medical Center Groningen.

Institute D' Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES

Albert Pol

The Lipid Trafficking and Disease group, supervised by Albert Pol, was founded in 2001 to characterize the cellular processes regulated or altered due to lipid accumulation within cells and how these processes determine animal’s physiology and human disease. 

University Medical Center Hamburg-Eppendorf, DE

Pablo Sáez

Prof. Dr. Pablo J. Sáez (born 1984), recently appointed in the Department of Biochemistry and Molecular Cell Biology at UKE. He has a large international network of collaborators due to his international training. His main expertise is in cell communication and cell migration using novel techniques (i.e. microfluidics and micropatterning). The consortium will benefit from his expertise on lyososomal calcium channels, as well as his expertise in cell signaling (ER-stress) induced by obesity.

AstraZeneca, UK

Helen Boyd

Helen Boyd is a biochemist and has worked in the pharmaceutical industry for over 25 years. This has involved working as a laboratory scientist, a scientific team leader and more recently in business planning and operations. Helen has supervised a number of PhD students, post-doctoral scientists and has published over 20 peer review papers.

AstraZeneca, UK

Kevin Moreau

Kevin Moreau is the PROTAC safety leader at AstraZeneca. Before joining AstraZeneca, Kevin was a Principal Investigator at the University of Cambridge, UK. Kevin is a protein trafficking expert, having worked on protein degradation for more than 10 years, notably in the autophagy-lysosomal field. Kevin has published more than 25 peer review papers including papers in Cell, Nature Cell Biology, Journal of Cell Biology and Nature Communications.

University of Helsinki, FIN

Elina Ikonen

Professor Elina Ikonen, MD PhD, leads the Lipid Trafficking Lab at the Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki. She is the Chair of the HiLIFE BioImaging platform, Director of the Biomedicum Imaging Unit, EMBO member and European Coordinator of Foundation Leducq Transatlantic Network of Excellence in Cellular and systemic cholesterol transport in physiology and disease. She has previously supervised 15 postdoctoral fellows and 12 PhD theses into completion.  

Academic Medical Centre Amsterdam, NL

Noam Zelcer

The local PI, Prof dr Noam Zelcer leads an independent research group in the Department of Medical Biochemistry of the AMC (5 PhDs, 3 Postdoc, and 3 technician) and is a holder of an ERC Consolidator grant, an NWO Vici grant, and is an Established Investigator of the Dutch Heart Society. He puts great emphasize on mentoring his trainees and facilitating their growth towards scientific independence. 

Nebion, CH

Philip Zimmermann

Philip Zimmermann studied agronomy at ETH Zurich, performed a PhD in molecular biology and a post-doc in bioinformatics at ETH Zurich. After this post-doc he became oberassistant at ETH Zurich where he started the development of the Genevestigator platform. In 2008 NEBION was founded as a spin-off company where Philip currently is CEO.

Utrecht University, NL

Alain de Bruin

Alain de Bruin is the head of department Biomolecular Health Sciences at the Faculty of Veterinary Medicine. He obtained his DVM degree in 1994 at University of Hannover, Germany. He performed his PhD research in the field of cancer biology and graduated in 1999 at the University of Berne, Switzerland. From 1999-2005, he was a veterinary anatomic pathology resident and postdoctoral fellow at the Ohio State University, USA. In 2005 he was appointed as full Professor in Pathobiology at Utrecht University.

InteRNA, Utrecht, NL

Roel Schaapveld

CEO. Dr. Schaapveld joined InteRNA Technologies as the first employee in February 2008 as Chief Operating Officer and was named Chief Executive Officer in May 2009 to manage the company’s day-to-day operations and to develop the company’s strategy and opportunities for further development. Prior to InteRNA he was senior manager in the corporate finance biotech team at Dutch merchant bank Kempen & Co. Roel brings along more than 8 years’ experience in product and business development. He held several positions at KREATECH Biotechnology, among which VP Corporate and Business Development. Roel holds a M.Sc. in Molecular Biology and received his Ph.D. from the University of Nijmegen, the Netherlands. During his academic career he worked at the Roche Institute for Molecular Biology (Nutley, NJ), the Dana-Farber Cancer Institute (Boston, MA) and at the Netherlands Cancer Institute in Amsterdam. Roel received his MBA from Nyenrode Business School, The Netherlands.

InteRNA, Utrecht, NL

Sanaz Yahyanejad

Sanaz Yahyanejad is the associate director of research and development at InteRNA Technologies. Dr. Yahyanejad obtained a master’s degree in medical biotechnology at Wageningen University then a doctorate from Maastricht University in the field of cancer biology involving basic and therapeutic aspects for cancer treatment. This was followed by research abroad as a postdoctoral fellow at Western University/London reginal cancer center – London, Ontario, Canada. Dr. Yahyanejad returned to the Netherlands and joined InteRNA in 2017 and since has been responsible for day-to-day research activities directing and preparing candidate drugs for clinical development.

Institute D' Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES

Marta Bosch

Marta Bosch is the senior associate researcher at the Lipid Trafficking and Disease group, headed by Albert Pol. Her research is involved in the study of the cellular processes related to lipid homeostasis, lipid droplet and mitochondrial physiology and energetic metabolism. Since early this year, she has been appointed Tenure-eligible lecturer in the Department of Biomedical Sciences at the University of Barcelona

PhD students

University of Bristol, UK

Shrestha Shaw

University of Bristol, UK

Rebeka Butkovic

AstraZeneca, UK

Camilla Ruffilli

University Medical Centre Utrecht, NL

Matteo Tantucci

University of Helsinki, FIN

Annabel Goudriaan

Academic Medical Centre Amsterdam, NL

Klevis Ndoj

Helmholtz Institute, Munich, DE

Carmen Paredes Yubero

University of Utrecht, NL

Orsolya Farkas

University Medical Center Groningen, NL

Lorinda van Dyk

University Medical Center Groningen, NL

Ankia Visser

University Medical Center Hamburg-Eppendorf, DE

Kendy Urdaneta

University Medical Center Hamburg-Eppendorf, DE

David McGrath

InteRNA, Utrecht, NL

Alejandra Puentes

University of Bristol, UK

Shrestha Shaw

University of Bristol, UK

Rebeka Butkovic

AstraZeneca, UK

Camilla Ruffilli

University Medical Centre Utrecht, NL

Matteo Tantucci

University of Helsinki, FIN

Annabel Goudriaan

Academic Medical Centre Amsterdam, NL

Klevis Ndoj

Helmholtz Institute, Munich, DE

Carmen Paredes Yubero

University of Utrecht, NL

Orsolya Farkas

University Medical Center Groningen, NL

Lorinda van Dyk

University Medical Center Groningen, NL

Ankia Visser

University Medical Center Hamburg-Eppendorf, DE

Kendy Urdaneta

University Medical Center Hamburg-Eppendorf, DE

David McGrath

InteRNA, Utrecht, NL

Alejandra Puentes

Check the PhD position that is still open

Partners